Exelixis Reports Positive Data From Post-hoc Exploratory Analysis Of Phase 3 CheckMate -9ER Trial


(RTTNews) – Exelixis, Inc. (EXEL) said data from a post-hoc exploratory analysis of the phase 3 CheckMate -9ER pivotal trial demonstrated efficacy benefits regardless of prior nephrectomy status with CABOMETYX in combination with Bristol Myers Squibb’s OPDIVO versus sunitinib for patients with previously untreated advanced renal cell carcinoma. Progression-free survival and objective response rate benefits were observed with combination regimen in the study.

The company said these findings show that CABOMETYX in combination with OPDIVO is a valuable first-line treatment option that improves outcomes for Kidney cancer patients who do not have a prior nephrectomy.

CheckMate -9ER is an open-label, randomized, multi-national phase 3 trial evaluating patients with previously untreated advanced or metastatic renal cell carcinoma with a clear cell component.